CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

By precisely editing the D3 gene, which regulates both plant height and tillering, researchers developed compact, ...

A research team has successfully engineered a japonica rice variety using CRISPR/Cas9 to simultaneously optimize plant ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...